With a frequency of 12%–63%, a large subset of CML patients suffer from TKI failure due to resistance related to mutations in the BCR::ABL1 kinase or more seldomly its amplification or overexpression (Tadesse et al., 2021). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.